Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model.

Blood
Ida HildenSøren Erik Bjørn

Abstract

Hemophilia is treated by IV replacement therapy with Factor VIII (FVIII) or Factor IX (FIX), either on demand to resolve bleeding, or as prophylaxis. Improved treatment may be provided by drugs designed for subcutaneous and less frequent administration with a reduced risk of inhibitor formation. Tissue factor pathway inhibitor (TFPI) down-regulates the initiation of coagulation by inhibition of Factor VIIa (FVIIa)/tissue factor/Factor Xa (FVIIa/TF/FXa). Blockage of TFPI inhibition may facilitate thrombin generation in a hemophilic setting. A high-affinity (K(D) = 25pM) mAb, mAb 2021, against TFPI was investigated. Binding of mAb 2021 to TFPI effectively prevented inhibition of FVIIa/TF/FXa and improved clot formation in hemophilia blood and plasma. The binding epitope on the Kunitz-type protease inhibitor domain 2 of TFPI was mapped by crystallography, and showed an extensive overlap with the FXa contact region highlighting a structural basis for its mechanism of action. In a rabbit hemophilia model, an intravenous or subcutaneous dose significantly reduced cuticle bleeding. mAb 2021 showed an effect comparable with that of rFVIIa. Cuticle bleeding in the model was reduced for at least 7 days by a single intravenous dose of mAb...Continue Reading

References

Nov 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·M S BajajS P Bajaj
Jul 1, 1995·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·E ErhardtsenO Nordfang
Mar 21, 1998·The Journal of Biological Chemistry·R J BaughS Krishnaswamy
Nov 2, 2005·The Journal of Pathology·Bashir A Lwaleed, Paul S Bass
Oct 24, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·James T B Crawley, David A Lane
Feb 12, 2008·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Susan A Maroney, Alan E Mast
Dec 4, 2008·Thrombosis Research·David Lillicrap
Feb 24, 2010·Thrombosis Research·Susan A MaroneyAlan E Mast

❮ Previous
Next ❯

Citations

Oct 16, 2013·Proceedings of the National Academy of Sciences of the United States of America·Jeremy P WoodAlan E Mast
Aug 28, 2013·The Journal of Clinical Investigation·George J Broze, Thomas J Girard
Dec 10, 2013·Hematology·Randal J Kaufman, Jerry S Powell
Feb 27, 2014·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Henrik AgersøIda Hilden
Mar 14, 2013·Journal of Thrombosis and Haemostasis : JTH·S A MaroneyA E Mast
Jul 17, 2013·Journal of Thrombosis and Haemostasis : JTH·F PeyvandiS Seregni
Apr 26, 2014·Haemophilia : the Official Journal of the World Federation of Hemophilia·J Oldenburg, T Albert
Dec 19, 2014·Haemophilia : the Official Journal of the World Federation of Hemophilia·S Shetty, K Ghosh
Jul 8, 2015·Journal of Thrombosis and Haemostasis : JTH·J S Powell
Jul 8, 2015·Journal of Thrombosis and Haemostasis : JTH·S A Maroney, A E Mast
May 1, 2015·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Charles L PercyPeter W Collins
May 3, 2014·Thrombosis Research·Cecilia AugustssonLars C Petersen
Mar 13, 2014·Blood·Jeremy P WoodAlan E Mast
Sep 26, 2013·Blood·Randal J Kaufman, Jerry S Powell
Dec 10, 2014·Blood Cells, Molecules & Diseases·Shrimati D Shetty, Kanjaksha Ghosh
Feb 20, 2015·Hematology·Jerry S Powell
May 22, 2016·Thrombosis Research·Julie A PetersonAlan E Mast
May 22, 2016·Thrombosis Research·Rodney M Camire
Jul 14, 2016·Haemophilia : the Official Journal of the World Federation of Hemophilia·M ShimaR Kruse-Jarres
May 8, 2016·Journal of Thrombosis and Haemostasis : JTH·P M MannucciM Franchini
Jul 1, 2016·Journal of Thrombosis and Haemostasis : JTH·E L G PryzdialW P Sheffield
Aug 23, 2016·Expert Opinion on Emerging Drugs·Massimo Morfini, Ezio Zanon
Oct 21, 2016·Journal of Thrombosis and Haemostasis : JTH·F PeyvandiE Biguzzi
Dec 27, 2016·Expert Review of Hematology·Lize F D van VulpenMichael Makris
Jan 24, 2018·British Journal of Haematology·Gavin LingEdward G D Tuddenham
May 2, 2018·Research and Practice in Thrombosis and Haemostasis·L LeongJ W Weisel
Oct 12, 2017·Blood·Valder R ArrudaBenjamin J Samelson-Jones
Jun 9, 2018·Nature Reviews. Drug Discovery·Rob Peters, Tim Harris
May 18, 2018·Blood·Michael U CallaghanSteven W Pipe
Nov 26, 2015·Arteriosclerosis, Thrombosis, and Vascular Biology·Alan E Mast
Aug 24, 2018·Journal of Thrombosis and Haemostasis : JTH·H EichlerP Chowdary
Dec 19, 2018·Blood·Angela C Weyand, Steven W Pipe
May 1, 2019·Expert Opinion on Biological Therapy·Giancarlo Castaman, Silvia Linari
Nov 28, 2013·The Journal of Biological Chemistry·Michael DockalFriedrich Scheiflinger
Oct 2, 2019·Journal of Thrombosis and Haemostasis : JTH·Josefin Ahnström
Nov 8, 2019·Blood·Alvin H Schmaier

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.